NovelStem International (OTCMKTS:NSTM – Get Free Report) is one of 78 publicly-traded companies in the “Diagnostics & Research” industry, but how does it compare to its competitors? We will compare NovelStem International to related businesses based on the strength of its risk, earnings, dividends, analyst recommendations, institutional ownership, valuation and profitability.
Earnings and Valuation
This table compares NovelStem International and its competitors top-line revenue, earnings per share and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
NovelStem International | $10,000.00 | -$4.19 million | -1.05 |
NovelStem International Competitors | $849.38 million | $43.67 million | -193.93 |
NovelStem International’s competitors have higher revenue and earnings than NovelStem International. NovelStem International is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Institutional & Insider Ownership
Analyst Ratings
This is a breakdown of recent ratings and price targets for NovelStem International and its competitors, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
NovelStem International | 0 | 0 | 0 | 0 | N/A |
NovelStem International Competitors | 78 | 422 | 478 | 7 | 2.42 |
As a group, “Diagnostics & Research” companies have a potential upside of 5.71%. Given NovelStem International’s competitors higher possible upside, analysts plainly believe NovelStem International has less favorable growth aspects than its competitors.
Profitability
This table compares NovelStem International and its competitors’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
NovelStem International | -9,166.67% | N/A | -73.18% |
NovelStem International Competitors | -415.67% | -798.15% | -22.91% |
Volatility & Risk
NovelStem International has a beta of 0.33, indicating that its stock price is 67% less volatile than the S&P 500. Comparatively, NovelStem International’s competitors have a beta of -0.41, indicating that their average stock price is 141% less volatile than the S&P 500.
Summary
NovelStem International competitors beat NovelStem International on 7 of the 10 factors compared.
NovelStem International Company Profile
NovelStem International Corp., a development stage biotechnology holding company, focuses on development and commercialization of stem cell-based diagnostic technology for cancer treatments and to reduce resistance to chemotherapy. The company was formerly known as Hollywood Media Corp. and changed its name to NovelStem International Corp. in September 2018. NovelStem International Corp. was incorporated in 1993 and is headquartered in Boca Raton, Florida.
Receive News & Ratings for NovelStem International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovelStem International and related companies with MarketBeat.com's FREE daily email newsletter.